CoreCap Advisors LLC Has $5.22 Million Position in Eli Lilly and Company (NYSE:LLY)

CoreCap Advisors LLC raised its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 5.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,758 shares of the company's stock after acquiring an additional 355 shares during the period. CoreCap Advisors LLC's holdings in Eli Lilly and Company were worth $5,217,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of LLY. Highline Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company by 80.0% in the 4th quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock valued at $35,000 after purchasing an additional 20 shares in the last quarter. FPC Investment Advisory Inc. boosted its stake in Eli Lilly and Company by 358.3% in the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock valued at $45,000 after buying an additional 43 shares in the last quarter. Prudent Man Investment Management Inc. acquired a new stake in Eli Lilly and Company in the fourth quarter valued at about $48,000. Compass Financial Services Inc bought a new position in Eli Lilly and Company in the fourth quarter valued at about $50,000. Finally, Fiduciary Advisors Inc. acquired a new position in Eli Lilly and Company during the fourth quarter worth about $58,000. 82.53% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares of the company's stock, valued at $4,778,521.60. This represents a 14.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.14% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $776.26 on Wednesday. The business has a 50-day moving average price of $820.91 and a two-hundred day moving average price of $814.03. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The company has a market cap of $735.69 billion, a P/E ratio of 66.29, a PEG ratio of 1.40 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The business had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same period in the prior year, the business earned $2.58 EPS. The company's revenue for the quarter was up 45.2% on a year-over-year basis. As a group, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be issued a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.77%. The ex-dividend date of this dividend is Friday, May 16th. Eli Lilly and Company's payout ratio is 48.82%.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. UBS Group decreased their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a report on Friday, May 2nd. Hsbc Global Res cut shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research note on Monday, April 28th. HSBC cut Eli Lilly and Company from a "buy" rating to a "reduce" rating and dropped their price target for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. Leerink Partners set a $950.00 price objective on Eli Lilly and Company in a research report on Friday, January 17th. Finally, Citigroup dropped their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research report on Tuesday, January 28th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $1,002.80.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.